{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:47:12Z","timestamp":1774442832972,"version":"3.50.1"},"reference-count":110,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T00:00:00Z","timestamp":1319760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:p>\n                    <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Historically, therapies for CRPC have primarily been chemotherapy\u2010based. A variety of novel therapeutics for CRPC have recently been developed and tested. When evaluating novel therapies for CRPC, there are various different endpoints that can be assessed.<\/jats:p>\n                  <jats:p>Novel treatments for CRPC to be discussed include docetaxel\u2010based combinations, new cytotoxic agents, immunotherapeutics, and targeted therapies. We evaluate prostate\u2010specific antigen, circulating tumour cells, progression\u2010free survival, overall survival, and other endpoints used in clinical trials.<\/jats:p>\n                  <jats:p>\n                    <jats:list list-type=\"explicit-label\">\n                      <jats:list-item>\n                        <jats:p>Androgen\u2010deprivation therapy is the initial treatment for metastatic prostate cancer. Although highly effective, all men who live long enough will eventually experience disease progression and develop castration resistance. Patients who have castration\u2010resistant prostate cancer (CRPC) have a median survival of \u22481\u20133 years.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>When evaluating novel therapies for CRPC, one must consider the endpoints measured for determination of response. We will discuss PSA, circulating tumour cells, progression\u2010free survival, overall survival, and other endpoints used in clinical trials.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Docetaxel and sipuleucel\u2010T are currently the preferred first\u2010line treatment options for patients with CRPC; cabazitaxel is a new option for patients after docetaxel failure.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Patients with CRPC historically have very poor survival, underscoring the unmet need for novel therapeutics. Although many agents appear promising, well\u2010designed randomized phase III trials are necessary to establish their impact on survival and health\u2010related quality of life.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Promising new therapies include hormonal agents, such as abiraterone and MDV3100, as well as other novel immunotherapeutics and anti\u2010prostate\u2010specific membrane antigen therapies. In the future, we anticipate therapies tailored to individual patients' malignancies using various molecular analyses.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:p>","DOI":"10.1111\/j.1464-410x.2011.10643.x","type":"journal-article","created":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T06:56:43Z","timestamp":1319785003000},"page":"968-985","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Novel therapeutics for the management of castration\u2010resistant prostate cancer (CRPC)"],"prefix":"10.1111","volume":"109","author":[{"given":"Daniel J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene K.","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin M.","family":"Dubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F.","family":"Chromecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harun","family":"Fajkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas S.","family":"Scherr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott T.","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,10,28]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20073"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2009.11.011"},{"key":"e_1_2_8_4_2","first-page":"4363","article-title":"Screening for prostate cancer: an update","volume":"15","author":"Shariat SF","year":"2008","journal-title":"Can J Urol"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.09.121"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656561003677382"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32832a1868"},{"key":"e_1_2_8_8_2","first-page":"58","article-title":"Beyond prostate\u2010specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer","volume":"6","author":"Shariat SF","year":"2004","journal-title":"Rev Urol"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21004"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9810"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.12.794"},{"key":"e_1_2_8_13_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0031-6997(24)01480-7","article-title":"The control of prostate\u2010specific antigen expression and gene regulation by pharmacological agents","volume":"53","author":"Dixon SC","year":"2001","journal-title":"Pharmacol Rev"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0664"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3461"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-1764-5"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60172-9"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2010.08.005"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0872"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.5170"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000403"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1039\/b917959c"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.074"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4524"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.8197"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23163"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8815"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2145"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn784"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.8771"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25421"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23669"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2937"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24429"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5252"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.11.002"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1691"},{"key":"e_1_2_8_41_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.5061","article-title":"Dasatinib and docetaxel combination treatment for patients with castration\u2010resistant progressive prostate cancer: a phase I\/II study (CA180086)","volume":"27","author":"Araujo J","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_42_2","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1200\/jco.2008.26.15_suppl.5140","article-title":"Phase II trial of 177Lutetium radiolabeled anti\u2010prostate\u2010specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu\u2010J591) in patients (pts) with metastatic castrate\u2010resistant prostate cancer (metCRPC)","volume":"26","author":"Tagawa ST","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.1281"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.0642"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1159\/000084201"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11829"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.09.015"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.02.020"},{"key":"e_1_2_8_49_2","doi-asserted-by":"crossref","first-page":"272s","DOI":"10.1200\/jco.2009.27.15_suppl.5156","article-title":"A phase I open\u2010label study using lenalidomide and docetaxel in castration\u2010resistant prostate cancer","volume":"27","author":"Petrylak DP","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_50_2","first-page":"1077","article-title":"Human prostate cancer cells: inhibition of proliferation by vitamin D analogs","volume":"14","author":"Schwartz G","year":"1994","journal-title":"Anticancer Res"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1291"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi002189x"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-09-0277"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10047"},{"key":"e_1_2_8_55_2","first-page":"170","article-title":"Testosterone\u2010repressed prostate message\u20102 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer","volume":"60","author":"Miyake H","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_8_56_2","first-page":"1932","article-title":"Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone\u2010refractory prostate cancer treated on Cancer and Leukemia Group B 9480","volume":"7","author":"George D","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.142"},{"key":"e_1_2_8_58_2","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1200\/jco.2010.28.18_suppl.lba4511","article-title":"A randomized, double\u2010blind, placebo\u2010controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration\u2010resistant prostate cancer (mCRPC): survival results of CALGB 90401","volume":"28","author":"Kelly W","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000131681.21637.b2"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2009.08.005"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.4448"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn665"},{"key":"e_1_2_8_63_2","article-title":"Phase II study of first\u2010line sagopilone combined with prednisone in patients with metastatic castration\u2010resistant prostate cancer (CRPC)","volume":"27","author":"Beer TM","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_64_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.5141","article-title":"Phase II study of sagopilone (ZK\u2010EPO) plus prednisone as first\u2010line chemotherapy in patients with metastatic androgen\u2010independent prostate cancer (AIPC)","volume":"26","author":"Graff J","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_65_2","unstructured":"de BonoJS MarotoP CalvoEet\u2003al.Phase II study of eribulin mesylate (E7389) in patients with metastatic castration\u2010resistant prostate cancer (CRPC) stratified by prior taxane therapy. Genitourinary Cancer Symposium 2009. Available at:http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20383"},{"key":"e_1_2_8_66_2","unstructured":"SmallE DemkowT GerritsenWRet\u2003al.A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic castration\u2010resistant prostate cancer. Genitourinary Cancer Symposium 2009. Available at:http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20295"},{"key":"e_1_2_8_67_2","unstructured":"HiganoC SaadF SomerBet\u2003al.A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic castration\u2010resistant prostate cancer. Genitourinary Cancer Symposium 2009. Available at:http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20543"},{"key":"e_1_2_8_68_2","article-title":"Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"26","author":"Beer TM","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3529"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0995-944"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22996"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0333"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2985"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp323"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-107"},{"key":"e_1_2_8_76_2","first-page":"1807","article-title":"Expression of the prostate\u2010specific membrane antigen","volume":"54","author":"Israeli R","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.154"},{"key":"e_1_2_8_79_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8097"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.160"},{"key":"e_1_2_8_81_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.4667"},{"key":"e_1_2_8_82_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24795"},{"key":"e_1_2_8_83_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.tps247","article-title":"Phase I Dose Escalation Study of Docetaxel\/Predisone and Fractionated 177Lu \u2010J591 for Metastatic Castrate Resistant Prostate Cancer (metCRPC)","volume":"28","author":"Beltran H","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_84_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.4667","article-title":"A randomized phase II trial of 177lu radiolabeled monoclonal antibody J591 (177Lu\u2010J591) and ketoconazole in patients (pts) with high\u2010risk castrate biochemically relapsed prostate cancer (PC) after local therapy","volume":"28","author":"Tagawa ST","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_85_2","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1200\/jco.2009.27.15_suppl.5046","article-title":"Phase II multicenter study of chemotherapy (chemo)\u2010naive castration\u2010resistant prostate cancer not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone","volume":"27","author":"Ryan C","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_86_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9259"},{"key":"e_1_2_8_87_2","unstructured":"De BonoJ LogothetisCJ FizaziKet\u2003al.Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration\u2010resistant prostate cancer (mCRPC) who have progressed after docetaxel\u2010based chemotherapy (chemo): results of COU\u2010AA\u2010301 a randomized double\u2010blind placebo\u2010controlled phase III study. 35th ESMO Congress.2010; Abstract LBA5"},{"key":"e_1_2_8_88_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.12.065"},{"key":"e_1_2_8_89_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07019.x"},{"key":"e_1_2_8_90_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3283355211"},{"key":"e_1_2_8_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"e_1_2_8_92_2","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1200\/jco.2008.26.15_suppl.5003","article-title":"Satraplatin in patients with advanced hormone\u2010refractory prostate cancer (HRPC): overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial","volume":"26","author":"Sartor AO","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_93_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22811"},{"key":"e_1_2_8_94_2","article-title":"Ixabepilone, mitoxantrone, and prednisone for metastatic castration\u2010resistant prostate cancer after docetaxel\u2010based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium","author":"Harzstark AL","year":"2010","journal-title":"Cancer"},{"key":"e_1_2_8_95_2","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1200\/jco.2009.27.15_suppl.5139","article-title":"A phase II study of patupilone in patients (pts) with metastatic castration\u2010 resistant prostate cancer (CRPC) who have progressed after docetaxel","volume":"27","author":"Beardsley EK","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_96_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21559"},{"key":"e_1_2_8_97_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.19.1458"},{"key":"e_1_2_8_98_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh141"},{"key":"e_1_2_8_99_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.147"},{"key":"e_1_2_8_100_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.042"},{"key":"e_1_2_8_101_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.18_suppl.lba4507"},{"key":"e_1_2_8_102_2","first-page":"79","article-title":"Effects of low\u2010dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial","volume":"43","author":"Sciuto R","year":"2002","journal-title":"J Nucl Med"},{"key":"e_1_2_8_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03639-4"},{"key":"e_1_2_8_104_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10437"},{"key":"e_1_2_8_105_2","first-page":"1150","article-title":"The PLACORHEN study: a double\u2010blind, placebo\u2010controlled, randomized radionuclide study with (186)Re\u2010etidronate in hormone\u2010resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study","volume":"43","author":"Han S","year":"2002","journal-title":"J Nucl Med"},{"key":"e_1_2_8_106_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.9811"},{"key":"e_1_2_8_107_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.060"},{"key":"e_1_2_8_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70147-X"},{"key":"e_1_2_8_109_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809003"},{"key":"e_1_2_8_110_2","first-page":"157","article-title":"Painful osteoblastic metastases: the role of nuclear medicine","volume":"15","author":"Silberstein E","year":"2001","journal-title":"Oncology"},{"key":"e_1_2_8_111_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.689"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2011.10643.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2011.10643.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:50:03Z","timestamp":1761756603000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2011.10643.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,28]]},"references-count":110,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1111\/j.1464-410X.2011.10643.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2011.10643.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,28]]},"assertion":[{"value":"2011-10-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}